Pluristem Therapeutics is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Co.'s product candidates include: placenta expanded (PLX)-peripheral arterial disease, which is in a multinational clinical trial in critical limb ischemia, in recovery following surgery for hip fracture, and in the treatment of severe coronavirus-19 cases complicated by Acute Respiratory Distress Syndrome (ARS); and PLX-R18, which is under development in the United States for ARS, as well as in a trial in the United States and Israel for incomplete hematopoietic recovery following hematopoietic cell transplantation. The PSTI stock yearly return is shown above.
The yearly return on the PSTI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PSTI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|